1. Nucleic Acid Aptamers for Diagnostics and Therapeutics:
Global Markets
Report Details:
Published:October 2012
No. of Pages: 138
Price: Single User License – US$4850
This research on Nucleic Acid Aptamers Market for Diagnostics and Therapeutics provides:
•An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic
purposes, with a focus on applications judged to be commercially viable rather than enabling of
basic research
•Analyses of global market trends, with data from 2011, estimates for 2012, and projections of
compound annual growth rates (CAGRs) through 2017
•Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA
delivery, vaccines, and antisense technologies
•Examination of high growth and market potential segments of the industry, and new and
established companies in the arena
•Comprehensive company profiles of major players in the industry.
The goal of this study is to determine and describe the specific applications and global market
demand for nucleic acid aptamers for therapeutic and diagnostic purposes. The report covers a
10-year period from 2008 to 2017. The original version of this report (BIO071A) was released in
March 2010. Thus, while some of the data tables still include historical information, the focus of
the most table updates is on the years 2011 with market predictions from 2012 to 2017. The years
covered in the table are given in small increments due to the early nature of the market and a
need to estimate as closely as possible small fluctuations, such as some recent and upcoming
patent expirations that may have a disproportionate effect on this market, compared with any
larger more mature markets. In addition to a breakdown by therapeutic or diagnostic application,
markets are further divided by major disease type addressed, or diagnostic application (i.e.,
clinical, environmental, biodefense, etc.).
We also identify emerging technology growth opportunities in aptamer use as adjuvants for siRNA
delivery, vaccines, and antisense technologies.
Although this report focuses on the 2008 to 2017 time frame, significant recent investments in
aptamer technology indicates that the therapeutic modality may remain important for some time to
come. Thus, while the aptamer field is yet an emerging niche of biotechnology, we highlight high
growth and market potential segments of the industry and new as well as established companies

2. in the arena.
In addition to a quantitative market analysis, this report includes a significant summary of the
intellectual property landscape and thus will be particularly useful to companies deciding whether
or not to enter the aptamer space. Finally, the study will be useful for the ever-increasing number
of diagnostic and biosensor development start-ups interested in the unique aspects of aptamers
as inexpensive, synthetic ligands for molecular recognition.
REASONS FOR DOING THE STUDY
Although aptamers and their directed selection in the laboratory were described in 1990, their
widespread acceptance in therapeutics and diagnostics is still being realized. Aptamers have a
number of advantages over their antibody counterparts, which are discussed in detail within the
report. Perhaps most important in the therapeutic context, as nucleic acids, aptamers are readily
chemically synthesized and therefore are comparably easy to characterize over antibodies
produced by recombinant means. For similar reasons, aptamers are readily developed and used
by boutique developers of novel diagnostics and biosensors, and larger firms are beginning to take
notice. Finally, several of the initial patents in the aptamer field have recently expired, or are set to
soon expire, which will make for a change in the intellectual property landscape. This report is
therefore timely in that regard as well.
SCOPE OF REPORT
The scope of this report covers all major known applications of aptamers in the biotechnology
arena. Nevertheless, the study focuses on applications judged to be commercially viable rather
than enabling of basic research.
INTENDED AUDIENCE
This report should be of benefit to all executives and scientific personnel in the biotechnology
industry. Those familiar with the concepts involved in therapeutic antibodies should be well
prepared to receive the report. Similarly, those familiar with the role of antibodies in diagnostics
(i.e., immunoassays of any type) will also find the report useful because it will explain the extended
capability of aptamers in similar contexts.
INFORMATION SOURCES
BCC researchers surveyed biotechnology, pharmaceutical, and diagnostics companies to obtain
data for this study. Included were life-science research tools, drug, biotechnology, and DNA
synthesis firms, as well as leading life-science research institutions. We also spoke with industry
thought leaders and academics in the field. In addition, we compiled data from secondary
sources, including industry, trade, and government. Finally, active intellectual property
professionals in the area were consulted.
ANALYST CREDENTIALS
Dr. George William (“Bill”) Jackson, Ph.D., serves as a Senior Scientist at BioTex, Inc. in Houston,
Texas. Additionally, Dr. Jackson is founder and chief scientist of Base Pair Biotechnologies, Inc.,

3. a company specializing in aptamer discovery services. He is an active researcher in the molecular
biology and diagnostics field with numerous federal grants in the area. Particularly, he has served
as principal investigator (PI) on several projects utilizing aptamers for both sensing and
bioremediation. Most recently, he serves as PI on a research grant from the National Institutes of
Health to select “an aptamer to everything,” which was formally titled, “Platform for Massively
Parallel Selection of Aptamer Ligands.” He has served on peer review panels at the National
Institutes of Health and the Environmental Protection Agency on topics ranging from biodefense
and medical diagnostics to water quality. Dr. Jackson has authored more than 30 peer-reviewed
publications or conference proceedings and is the inventor on four issued and 13 pending patents.
Co-author, Dr. Ulrich Strych, Ph.D., is a Research Assistant Professor at the University of
Houston. Dr. Strych is an experienced molecular biologist who has collaborated with Dr. Jackson
for more than five years on various aptamer-related research projects. Dr. Strych has extensive
modern molecular biology experience, methods development know-how in surface plasmon
resonance (SPR) and other bioanalytical approaches, and hands-on experience with other
methods of high-throughput combinatorial screening, such as phage display.
Get your copy of this report @
http://www.reportsnreports.com/reports/71025-nucleic-acid-aptamers-for-diagnostics-and-therapeutics-global-
ma.html
Major points covered in Table of Contents of this report include
Chapter- 1: Introduction
Study Goals And Objectives
Reasons For Doing The Study
Scope Of Report
Intended Audience
Information Sources
Analyst Credentials
Related Bcc Reports
Bcc Online Services
Disclaimer
Chapter- 2: Summary 4
Table 0a : Global Markets For Aptamers, Through 2017
Figure Summary : Global Markets For Aptamers, 2011–2017
Table 0b : Potential Markets For Aptamer Therapeutics, Through 2017
Table 0c : Historical U.S. Sales For Macugen, The First Fda-Approved Aptamer Drug, 2005-2011
Table 0d : Potential Markets For Aptamer-Based In-Vitro Diagnostics, Through 2017
Chapter- 3: Overview 5
Introduction: Aptamers As Affinity Reagents

4. Chapter- 4: Markets By Technology Type 43
Introduction
Enabling Technology
Aptamers As Diagnostic Sensors
Aptamers As Therapeutics
Macugen's Path To Fda Approval
Clinical Trials Involving Aptamers
Market Leaders (U.S.)
Market Leaders (International)
Chapter- 5: Markets By Applications 20
Introduction
Application Of Aptamers As Diagnostics
Application Of Aptamers As Therapeutics
Chapter- 6: Intellectual Property Analysis 16
Brief History
Aptamers And Selex As Patentable Subject Matter
Original Aptamer And Selex Patents
Validity, Legal Action, And Infringement
Chapter- 7: Industry Structure And Competitive Analysis 9
Aptamer Technology In The Bioscience Industry
The Evolving Aptamer Ip Landscape
Aptamers And The Biotechnology Ecosystem
Porter Model Analysis Of The Aptamer Industry
Chapter- 8: Company Profiles 16
Abraxis Kits, Llc
Alimera Sciences
Alnylam Pharmaceuticals
Am Biotechnologies, Llc
Angiogenix
Aptagen, Llc
Aptamer Sciences Inc.
Aptasol (Aptamer Solutions) Ltd

5. Archemix Corp.
Anesiva, Inc.
Base Pair Biotechnologies, Inc.
Cynvenio Biosystems, Inc.
Cytogenix, Inc.
Envirologix, Inc.
Enzon Pharmaceuticals Inc.
Eyetech
Isis Pharmaceuticals
Mitsui & Co. (U.S.A.), Inc.
Neoventures
Noxxon
Ophthotech Corporation
Osi Pharmaceuticals, Inc.
Regado Biosciences
Rina Gmbh
Quest Diagnostics
Saw Instruments Gmbh
Somalogic, Inc.
Sumitomo Bakelite-North America, Inc.
Chapter- 9: References 22
References
List Of Tables
Summary Table A : Global Markets For Aptamers, Through 2017
Summary Table B : Potential Markets For Aptamer Therapeutics, Through 2017
Summary Table C : Historical U.S. Sales For Macugen, The First Fda-Approved Aptamer Drug,
2005-2011
Summary Table D : Potential Markets For Aptamer-Based In-Vitro Diagnostics, Through 2017
Table 1 : Aptamers And Antibodies: Key Differences
Table 2 : Modifications Employed To Enhance Aptamers
Table 3 : Current Price Per Megabase For 'Next Generation' Dna Sequencing
Table 4 : Medically Relevant Aptamer Targets
Table 5 : Aptamer Clinical Trials
Table 6 : Emerging Applications For Aptamers In Therapeutics
Table 7 : Number Of Nih Funded Grants Employing Aptamers, 2005–2011
Table 8 : Nih Funding For Diseases Considered As Possible Applications For Aptamers,
2008–2013
Table 9 : Nih Funding For Technologies Considered As Possible Applications For Aptamers,

6. 2008–2013
Table 10 : Total Nih Funding, 2005-2011
Table 11 : Number Of Publications In Isi Web Of Knowledge Under The Topic “Aptamer,” 2005-
2012
Table 12 : Example Of Veterinary Residue Tests (Elisas) Offered By A Leading U.S. Vendor
(Abraxis Kits, Llc)
Table 13 : Other Environmental Elisas Offered By Abraxis Kits, Llc1
Table 14 : Numbers Of Research Grants From The Usda On Zoonotic Diseases
Table 15 : Usda-Sponsored Research Grants On “Aptamers”
Table 16 : U.S. Diagnostics And Testing Markets In Which Aptamers Could Play A Significant
Role, Through 2017
Table 17 : Market Comparison (Macugen, Lucentis, And Avastin), 2004-2011
Table 18 : Global Therapeutics Markets Addressable In Near Term By Aptamers, Through 2017
Table 19 : Cancer Therapeutics Markets In The U.S. By Subindication, Through 2017
Table 20 : Major Holders Of Aptamer/Selex Ip
Table 21 : Strategic (Known Or Published) Technology And R&D Alliances
Table 22 : Selected Aptamer Patents
Table 23 : Selected U.S. Patent Applications For Therapeutic Aptamers
List Of Figures
Summary Figure : Global Markets For Aptamers, 2011–2017
Figure Sample Figure : Global Markets For Aptamers, 2011-2017
Figure 1 : Simplified Schematic Of Selex Process For In-Vitro Selection Of (Dna) Aptamers
Figure 2 : Comparison Of Traditional Small Molecule, Protein, And Aptamer-Based Modalities
Figure 3 : Aptamer Industry Structure
Figure 4 : Porter Analysis Of The Aptamer Industry
Contact: sales@reportsandreports.com for more information.